Farah Morgan is an Endocrinology/Metabolic physician affiliated with Cooper University Health Care. OpenAlex indexes 29 publications with 327 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1210 Brace Rd
Suite 107
Cherry Hill, NJ 080343213
Telephone
856-759-3597Registry record last updated 23 Feb 2015.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202410 payments
- SANOFI-AVENTIS U.S. LLCProgram year20241 payment
- Abbott LaboratoriesProgram year20235 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
58.7%Insulin Analog20.6%Lantus Solostar28%Humalog Kwikpen U-10017%Basaglar Kwikpen U-10011%Novolog Flexpen8%Humalog8%Tresiba Flextouch U-1005%Fiasp Flextouch4%Toujeo Solostar3%Insulin Lispro Kwikpen U-1003%Lyumjev Kwikpen U-1002%Lantus2%Tresiba Flextouch U-2002%Novolog2%Admelog Solostar2%Insulin Glargine-Yfgn2%Levemir Flexpen2%Humalog Kwikpen U-2001%Part D<11 patientsGLP-1 receptor agonist14.9%Ozempic51%Mounjaro26%Trulicity19%Victoza 3-Pak2%Rybelsus2%Part D<11 patients+ 9 more classes in this area
Hormonal (systemic)
26.8%l-Thyroxine22.8%Levothyroxine Sodium79%Synthroid17%Levoxyl3%Tirosint1%Part D<11 patientsThyroid Hormone Synthesis Inhibitor1.8%Methimazole100%Part D≥28 patients+ 4 more classes in this area
Cardiovascular
9.7%Statin4.9%Atorvastatin Calcium49%Rosuvastatin Calcium40%Pravastatin Sodium11%Part D<11 patientsACE inhibitor1.2%Lisinopril100%Part D≥16 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- SUN-762 Suspected Fibroblast Growth Factor 23 Mediated Hypophosphatemia in a Patient with Multiple Myeloma
Journal of the Endocrine Society
2025 - MON-351 A Case of Papillary Thyroid Cancer with Development of Non-Iodine-Avid, Non-Hypermetabolic Liver Metastasis
Journal of the Endocrine Society
2025
Similar KOLs
Other experts from the same institution or the same specialty.
David Warshal, MD
Cooper University Health Care
Elyce Cardonick, MD
Cooper University Health Care
Lawrence Weisberg, MD
Cooper University Health Care
Ignacio Valencia, MD
Cooper University Health Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”